VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-10
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.20%, a 5.00% increase year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 0.00%, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-12-31 was 3.80%, a 5.56% increase year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.00%, a 11.11% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.95%, a 11.04% decline from fiscal 2024.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.44%, a 13.27% increase from fiscal 2023.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.92%.
- VERU INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 1.53%, a 0.00% change from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-10 | 4.10% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-13 | 3.80% 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | 3.80% 10-Q · filed 2026-02-11 | |||||
| 2025-09-30 | 3.95% 10-K · filed 2025-12-17 | |||||
| 2025-06-30 | 4.00% 10-Q · filed 2026-08-10 | 4.00% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 4.10% 10-Q · filed 2026-05-13 | 3.60% 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | 3.60% 10-Q · filed 2026-02-11 | |||||
| 2024-09-30 | 4.44% 10-K · filed 2025-12-17 | |||||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-12 | 4.48% 10-Q · filed 2024-08-08 | 4.50% 10-Q · filed 2025-08-12 | 4.49% 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-08 | 4.60% 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 4.70% 10-Q · filed 2025-02-13 | |||||
| 2023-09-30 | 3.92% 10-K · filed 2024-12-16 | |||||
| 2023-06-30 | 3.51% 10-Q · filed 2024-08-08 | 3.92% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 3.84% 10-Q · filed 2023-05-11 | |||||
| 2022-06-30 | 3.01% 10-Q/A · filed 2023-11-15 | |||||
| 2022-03-31 | 2.50% 10-Q · filed 2023-05-11 | |||||
| 2017-09-30 | 1.53% 10-K · filed 2018-01-02 | |||||
| 2017-03-31 | 1.62% 10-Q · filed 2017-05-10 | |||||
| 2016-12-31 | 1.62% 10-Q · filed 2017-02-09 | |||||
| 2016-09-30 | 1.53% 10-K · filed 2016-12-12 | |||||
| 2016-06-30 | 1.53% 10-Q · filed 2016-07-28 | 1.53% 10-Q · filed 2016-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |